New drug duo tested in Tough-to-Treat breast cancer
NCT ID NCT05633979
Summary
This early-stage study is testing a new combination of two drugs, valemetostat and trastuzumab deruxtecan, for people with advanced breast cancer that has low or no HER2 protein. The main goals are to find a safe and effective dose and to see if the treatment can shrink tumors. It is for adults whose cancer has spread and who have already tried other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.